378 related articles for article (PubMed ID: 32746645)
1. Clinical heterogeneity in patients with non-alcoholic fatty liver disease-associated hepatocellular carcinoma.
Anastasopoulos NT; Lianos GD; Tatsi V; Karampa A; Goussia A; Glantzounis GK
Expert Rev Gastroenterol Hepatol; 2020 Nov; 14(11):1025-1033. PubMed ID: 32746645
[TBL] [Abstract][Full Text] [Related]
2. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
Streba LA; Vere CC; Rogoveanu I; Streba CT
World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
[TBL] [Abstract][Full Text] [Related]
3. Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease.
Bertot LC; Adams LA
Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):179-187. PubMed ID: 30791782
[TBL] [Abstract][Full Text] [Related]
4. Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: A Problem of Growing Magnitude.
Pocha C; Kolly P; Dufour JF
Semin Liver Dis; 2015 Aug; 35(3):304-17. PubMed ID: 26378646
[TBL] [Abstract][Full Text] [Related]
5. Rate of Nonsurveillance and Advanced Hepatocellular Carcinoma at Diagnosis in Chronic Liver Disease.
Huang Y; Wallace MC; Adams LA; MacQuillan G; Garas G; Ferguson J; Samuelson S; Tibballs J; Jeffrey GP
J Clin Gastroenterol; 2018 Jul; 52(6):551-556. PubMed ID: 28858944
[TBL] [Abstract][Full Text] [Related]
6. Clinical features of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without advanced fibrosis.
Kodama K; Kawaguchi T; Hyogo H; Nakajima T; Ono M; Seike M; Takahashi H; Nozaki Y; Kawanaka M; Tanaka S; Imajo K; Sumida Y; Kamada Y; Fujii H; Seko Y; Takehara T; Itoh Y; Nakajima A; Masaki N; Torimura T; Saibara T; Karino Y; Chayama K; Tokushige K
J Gastroenterol Hepatol; 2019 Sep; 34(9):1626-1632. PubMed ID: 30668889
[TBL] [Abstract][Full Text] [Related]
7. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
Perumpail RB; Wong RJ; Ahmed A; Harrison SA
Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
[TBL] [Abstract][Full Text] [Related]
8. AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review.
Loomba R; Lim JK; Patton H; El-Serag HB
Gastroenterology; 2020 May; 158(6):1822-1830. PubMed ID: 32006545
[TBL] [Abstract][Full Text] [Related]
9. Clinical features and management issues of NAFLD-related HCC: what we know so far.
Pugliese N; Alfarone L; Arcari I; Giugliano S; Parigi TL; Rescigno M; Lleo A; Aghemo A
Expert Rev Gastroenterol Hepatol; 2023 Jan; 17(1):31-43. PubMed ID: 36576057
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease.
Satapathy SK; Sanyal AJ
Semin Liver Dis; 2015 Aug; 35(3):221-35. PubMed ID: 26378640
[TBL] [Abstract][Full Text] [Related]
11. The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment.
Margini C; Dufour JF
Liver Int; 2016 Mar; 36(3):317-24. PubMed ID: 26601627
[TBL] [Abstract][Full Text] [Related]
12. Application of hepatocellular carcinoma surveillance in a European setting. What can we learn from clinical practice?
Edenvik P; Davidsdottir L; Oksanen A; Isaksson B; Hultcrantz R; Stål P
Liver Int; 2015 Jul; 35(7):1862-71. PubMed ID: 25524812
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease.
Makri E; Goulas A; Polyzos SA
Arch Med Res; 2021 Jan; 52(1):25-37. PubMed ID: 33334622
[TBL] [Abstract][Full Text] [Related]
14. Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease.
Wong CR; Njei B; Nguyen MH; Nguyen A; Lim JK
Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1061-1069. PubMed ID: 28960360
[TBL] [Abstract][Full Text] [Related]
15. Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link.
Chrysavgis L; Giannakodimos I; Diamantopoulou P; Cholongitas E
World J Gastroenterol; 2022 Jan; 28(3):310-331. PubMed ID: 35110952
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease.
Seif El Dahan K; Daher D; Singal AG
Clin Mol Hepatol; 2023 Feb; 29(Suppl):S207-S219. PubMed ID: 36103899
[TBL] [Abstract][Full Text] [Related]
17. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis.
Mohamad B; Shah V; Onyshchenko M; Elshamy M; Aucejo F; Lopez R; Hanouneh IA; Alhaddad R; Alkhouri N
Hepatol Int; 2016 Jul; 10(4):632-9. PubMed ID: 26558795
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease.
Wong CR; Nguyen MH; Lim JK
World J Gastroenterol; 2016 Oct; 22(37):8294-8303. PubMed ID: 27729736
[TBL] [Abstract][Full Text] [Related]
19. Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis.
Marengo A; Rosso C; Bugianesi E
Annu Rev Med; 2016; 67():103-17. PubMed ID: 26473416
[TBL] [Abstract][Full Text] [Related]
20. Should Patients With NAFLD/NASH Be Surveyed for HCC?
Reig M; Gambato M; Man NK; Roberts JP; Victor D; Orci LA; Toso C
Transplantation; 2019 Jan; 103(1):39-44. PubMed ID: 30080818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
